Barclays upgrades Demant stock rating on achievable guidance

Barclays upgraded Demant A/S from Underweight to Equalweight, raising the price target to DKK285.00, citing more achievable guidance post-Q1 reset and stabilizing EBIT downgrades. The upgrade reflects growing optimism from audiologists regarding Demant's market share and re-entry into managed care, along with potential benefits from a French market recovery, leading to a 1-2% increase in Barclays' EBIT estimates. Despite the upgrade, Barclays remains cautious due to challenging market conditions, preferring retail over wholesale, but now favors Demant within the wholesale segment.

Analysis

Barclays has upgraded Demant A/S to Equalweight from Underweight, raising its price target to DKK285.00 from DKK220.00, signaling a revised outlook based on more achievable guidance following Demant's Q1 reset. This reset is anticipated to stabilize consensus EBIT downgrades, which had reached 18% year-to-date for Demant compared to 4% for competitor Sonova. Positive catalysts underpinning the upgrade include growing optimism from audiologists regarding Demant's market share prospects and its re-entry into managed care, alongside its positioning to capitalize on a recovery in the French market. In line with this, Barclays has increased its EBIT estimates for Demant by 1-2%, placing them at the midpoint of the company’s current year guidance and aligning with consensus, reflecting these rebased expectations. However, Barclays maintains a cautious stance, citing "challenging market conditions" and an ongoing preference for retail over wholesale investments in the sector, though Demant is now its preferred name within the wholesale segment. The article also notes an external AI analysis by InvestingPro did not identify Demant as a top-tier undervalued stock, adding a nuanced perspective to its current valuation.

Key Decisions for Investors

• Investors could consider the Equalweight rating and increased price target as indicative of a stabilized, albeit still challenging, outlook for Demant.
• Focus on Demant's execution against its rebased guidance, progress in managed care re-entry, and market share developments, particularly in the recovering French market.
• Remain cognizant of persistent challenging market conditions and Barclays' broader sector preference for retail, even as Demant gains favor within the wholesale segment.